During 30 minutes of maintained ischaemia of the upper limb, the nerve action potential (NAP) persists in some uraemic patients until the end of the test, and in all patients significantly longer than in normal subjects. Such behaviour is similar to that seen in diabetic patients and unlike that seen in people receiving high doses of insulin and glucose perfusion. Renal dialysis increases this tendency, while macromolecular perfusion after dialysis tends to correct it.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC494142 | PMC |
| http://dx.doi.org/10.1136/jnnp.35.5.631 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pedal acceleration time is related to arterial stiffness in patients with chronic limb-threatening ischemia.
J Vasc Bras
February 2025
Faculdade Ciências Médicas de Minas Gerais, Belo Horizonte, MG, Brasil.
Background: Pedal acceleration time (PAT) is a novel indicator of peripheral arterial disease in the lower limbs. Elevated PAT values are associated with worse limb ischemia. Arterial stiffness indexes are another class of indicators recently studied in patients with chronic limb-threatening ischemia (CLTI).
View Article and Find Full Text PDFSecondary congenital nephrotic syndrome complicated by acute mesenteric ischemia: A case report.
Clin Nephrol Case Stud
March 2025
Department of Pediatric Rheumatology and Nephrology, and.
Thromboembolic events are among the most serious, yet rare complications of nephrotic syndrome. While peripheral venous thrombosis and pulmonary embolism are the most common, superior mesenteric artery thrombosis is a rare but life-threatening occurrence. We present a case of severe cytomegalovirus (CMV) infection complicated by congenital nephrotic syndrome, leading to mesenteric ischemia.
View Article and Find Full Text PDFIdentification of regulator gene and pathway in myocardial ischemia-reperfusion injury: a bioinformatics and biological validation study.
Hereditas
March 2025
Department of Cardiology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Background: Acute myocardial infarction (AMI) is the primary cause of cardiac mortality worldwide. However, myocardial ischemia-reperfusion injury (MIRI) following reperfusion therapy is common in AMI, causing myocardial damage and affecting the patient's prognosis. Presently, there are no effective treatments available for MIRI.
View Article and Find Full Text PDFThe FKBPL-based therapeutic peptide, AD-01, protects the endothelium from hypoxia-induced damage by stabilising hypoxia inducible factor-α and inflammation.
J Transl Med
March 2025
School of Life Sciences & Institute for Biomedical Materials and Devices, Faculty of Science, University of Technology Sydney, Sydney, NSW, Australia.
Background: Endothelial dysfunction is a hallmark feature of cardiovascular disease (CVD), yet the underlying mechanisms are still poorly understood. This has impeded the development of effective therapies, particularly for peripheral artery disease. FK506-binding protein like (FKBPL) and its therapeutic peptide mimetic, AD-01, are crucial negative regulators of angiogenesis, however their roles in CVD are unknown.
View Article and Find Full Text PDFAn exploratory study of high-throughput transcriptomic analysis reveals novel mRNA biomarkers for acute myocardial infarction using integrated methods.
Sci Rep
March 2025
Medical School, Kunming University of Science and Technology, Kunming, China.
Acute myocardial infarction (AMI) is a major contributor to cardiovascular-related mortality, and early diagnosis is crucial for effective treatment and better outcomes. While several biomarkers have been explored for AMI, there remains a need for reliable, non-invasive biomarkers that can accurately differentiate AMI patients from healthy individuals. This study aims to identify potential mRNA biomarkers in peripheral blood that could aid in the diagnosis and monitoring of AMI.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!